After the identification of BRAF mutations in a wide variety of human cancers, namely melanoma, ovarian carcinoma and microsatellite unstable colorectal carcinomas [13], we and others have reported a high prevalence (30% to 69%) of BRAF point mutations in PTC [14-18]. This evidence concerns the gene BRAF and ovarian carcinoma.